LUXCEPTAR
LIVE

Serial Number

79254181

Owner

Kiadis Pharma Netherlands B.V.

Filing Date

Dec 18, 2018

Add to watchlist:

No watchlists yet
View on USPTO

LUXCEPTAR Trademark

Serial Number: 79254181 • Registration: 5917334

LUXCEPTAR is a trademark filed by Kiadis Pharma Netherlands B.V. on December 18, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Kiadis Pharma Netherlands B.V.

Paasheuvelweg 25A

Entity Type: 98

Kiadis Pharma Intellectual Property B.V.

Paasheuvelweg 25A

Entity Type: 26

Trademark Details

Filing Date

December 18, 2018

Registration Date

November 26, 2019

Published for Opposition

September 10, 2019

Cancellation Date

June 12, 2026

Goods & Services

Medical and veterinary preparations and articles for the immune modulation; pharmaceuticals and natural remedies namely, natural remedy preparations for the immune modulation; medicines for the immune modulation; pharmaceuticals for the immune modulation and for the prophylaxis of immune system related diseases and disorders; pharmaceutical preparations, namely, preparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical drugs namely, preparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical implants namely, implantable intravenously drug delivery devices sold filled with pharmaceutical preparations for the immune modulation; pharmaceutical preparations for activating cellular function; cellular function activating agents for medical purposes; clinical medical reagents; cultures of microorganisms for medical use; medical preparations namely, pharmaceuticals and biological compounds to support the growth of stem cells; surgical implants comprised of living tissues grown from stem cells; medical diagnostic reagents; stem cells for research purposes; stem cells for medical purposes; reagents for blood grouping for medical purposes; anti-cancer drugs namely pharmaceuticals for the treatment of cancer; compounds namely, anti-cancer preparations for treating cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer

Human healthcare services; medical services; pharmaceutical consultancy services; medical diagnostic testing, monitoring, and reporting services; medical treatment services namely, medical diagnosis and treatment for the immune modulation and prophylaxis of immune system related diseases and disorders; surgical treatment services; medical services relating to the removal, treatment and processing of stem cells; analysis of human serum for medical treatment; analysis of human tissues for medical treatment

Filing History

CANCELLED SECTION 71
Jun 12, 2026 C71T
CHANGE OF OWNER RECEIVED FROM IB
Aug 9, 2024 CHLD
NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Apr 10, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 3, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 16, 2020 FICS
FINAL DISPOSITION PROCESSED
Mar 16, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 26, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2019 R.PR
PUBLISHED FOR OPPOSITION
Sep 10, 2019 PUBO
NOTICE OF PUBLICATION
Aug 21, 2019 NPUB
ASSIGNED TO LIE
Aug 8, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 29, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2019 TROA
REFUSAL PROCESSED BY IB
Apr 12, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 28, 2019 RFCS
REFUSAL PROCESSED BY MPU
Mar 28, 2019 RFRR
APPLICATION FILING RECEIPT MAILED
Mar 21, 2019 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 20, 2019 RFCR
NON-FINAL ACTION WRITTEN
Mar 19, 2019 CNRT
ASSIGNED TO EXAMINER
Mar 17, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 17, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 14, 2019 REPR